Enter multiple symbols separated by commas

Stocks Sequenom Inc


  • The Sequenom Syndrome Thursday, 30 Apr 2009 | 12:01 PM ET

    Shares of San Diego-based Sequenom are sinking on huge trading volume. The company shocked investors after the closing bell yesterday when it issued this press release announcing that its data couldn't be trusted.

  • A Large Options Bet on Sequenom Monday, 2 Mar 2009 | 8:51 AM ET

    At least one large options trader is placing a major bet on the upside for genetic analysis company Sequenom.

  • Sell Block: Death Is Big Business Thursday, 12 Feb 2009 | 9:29 PM ET

    This company makes its money in a very unique way. But is the stock worth buying?

  • Lightning Round OT: Atwood Oceanics, Sequenom and More Thursday, 5 Feb 2009 | 11:04 PM ET

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • Big Drugmaker, Bigger Mistake Thursday, 29 Jan 2009 | 6:07 PM ET

    Since announcing a merger with Wyeth, drugmaker Pfizer has slipped 13%. So, how should trade healthcare?

  • Sequenom Put To The Test Thursday, 29 Jan 2009 | 1:43 PM ET

    I need a break from blogging all-things Pfizer. Sequenom to the rescue with more data on its diagnostic test for Down Syndrome. Out of nearly 900 women there were no false negatives, but for the first time SQNM reported one false positive.

  • Making M&A Money in Big Pharma Friday, 23 Jan 2009 | 7:00 PM ET

    Who's next in the potential wave of consolidation set off by Pfizer and Wyeth? Cramer has an idea.

  • Four Hot Stocks in Four Diverse Sectors Thursday, 15 Jan 2009 | 11:47 AM ET

    Paul Noglows, director of research at Lazard Capital Markets, suggested four stock picks in four different sectors that will see growth over the year.

  • Speculating on Sequenom Friday, 19 Dec 2008 | 9:39 PM ET

    This company could revolutionize pregnancy testing, Cramer says, and make you a ton of money in the process.

  • Lightning Round OT: Apple, Immucor and More Monday, 10 Nov 2008 | 6:30 PM ET

    The Lightning Round is extended in this CNBC.com exclusive feature.